News from stealth biotherapeutics inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 23, 2021, 07:30 ET Stealth BioTherapeutics Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Feb 10, 2021, 07:55 ET Stealth BioTherapeutics Announces Pricing Of $4.7 Million Registered Direct Offering Of American Depositary Shares

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Jan 07, 2021, 16:30 ET Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Jan 05, 2021, 20:00 ET Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Dec 09, 2020, 16:30 ET Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Dec 07, 2020, 08:00 ET Stealth BioTherapeutics Announces Appointment of Eve E. Slater, M.D., F.A.C.C. to its Board of Directors

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Nov 24, 2020, 16:30 ET Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering

Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery,...

Nov 20, 2020, 08:00 ET Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering

Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery,...

Nov 05, 2020, 07:30 ET Stealth BioTherapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Nov 04, 2020, 17:00 ET Stealth BioTherapeutics Announces Development Financing To Advance Elamipretide Clinical Trials

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Oct 30, 2020, 16:30 ET Stealth BioTherapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Oct 19, 2020, 16:30 ET Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Sep 23, 2020, 16:30 ET Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting

Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Sep 10, 2020, 17:30 ET Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Aug 06, 2020, 07:30 ET Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Jul 30, 2020, 08:30 ET Stealth BioTherapeutics to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Jun 17, 2020, 08:30 ET Stealth BioTherapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

May 26, 2020, 16:30 ET Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

May 13, 2020, 08:30 ET Stealth BioTherapeutics to Present at UBS Virtual Global Healthcare Conference

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

May 07, 2020, 07:30 ET Stealth BioTherapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

May 04, 2020, 18:00 ET Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Apr 13, 2020, 08:25 ET Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...

Mar 03, 2020, 07:30 ET FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Feb 27, 2020, 18:00 ET Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...

Dec 20, 2019, 08:00 ET Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...